OncoMatch/Clinical Trials/NCT07814352
A Study of SX-682 in Combination With Proton Craniospinal Irradiation (pCSI) in People With Leptomeningeal Disease
Official title: A Phase Ib Trial of SX-682 (CXCR1/2 Inhibitor) Combined With Proton Craniospinal Irradiation for Patients With Leptomeningeal Disease
Is NCT07814352 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies SX-682 for leptomeningeal disease (lmd).
Treatment: SX-682 — The researchers are doing this study to find out whether SX-682 in combination with proton craniospinal irradiation (pCSI) is a safe treatment approach for people with melanoma or non-small cell lung cancer (NSCLC) with leptomeningeal disease (LMD). The researchers will also look at whether the treatment combination is effective against participants' cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard of care therapy
Patients will have progressed on standard of care therapies
Lab requirements
Blood counts
ANC ≥ 1,500 cells/mm3; Platelets ≥ 100,000 cells/mm3 (transfusion allowed); Hemoglobin ≥ 8 g/dl (transfusion allowed)
Kidney function
Creatinine clearance (CrCL) ≥30 mL/min by institutional standard
Liver function
Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN if Gilbert's); AST and ALT ≤3 x ULN (≤5 x ULN with liver mets)
Cardiac function
No history of unstable angina requiring hospitalization in last 3 months; No history of MI within last 3 months; NYHA Functional Classification II or better
Required Organ Function: Adequate hematologic, renal, hepatic, and cardiac function as defined
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities) · Commack, New York
- Memorial Sloan Kettering Commack (Limited Protocol Activities) · Commack, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07814352 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard of care therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify